Lotus Pharmaceutical Co., Ltd. (TPE:1795)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
193.00
-1.00 (-0.52%)
Aug 28, 2026, 1:30 PM CST

Lotus Pharmaceutical Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
3,7664,7205,0664,1063,0211,403
Depreciation & Amortization
2,0761,5261,2731,200926.96748.76
Other Amortization
9.29.4210.1310.239.9110.62
Loss (Gain) From Sale of Assets
4.0413.720.724.75-2.523.2
Asset Writedown & Restructuring Costs
316.17303.02159.99179.37136.67234.82
Loss (Gain) From Sale of Investments
-869.46-548.28-604.16-715.05-286.81-
Stock-Based Compensation
252.2279.38348.65106.4939.4157.66
Provision & Write-off of Bad Debts
-0.67-7.61-2.96-4.04-3.3334.24
Other Operating Activities
-150.18-572.03615.83144.35788.08460.19
Change in Accounts Receivable
-161.22,156-850.77-1,665-1,373-633.42
Change in Inventory
116.68-447.43-181.33-623.18-313.29-1,125
Change in Accounts Payable
294.59-127.59346.45-659.57648.39-980.98
Change in Unearned Revenue
-36.64-10.7832.93-69.3320-9.74
Change in Other Net Operating Assets
-1,119188.33-59.23-420.87108.67-83.63
Operating Cash Flow
4,4987,4826,1551,6143,719119.66
Operating Cash Flow Growth
-36.79%21.56%281.29%-56.60%3008.27%-93.86%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-1,352-1,320-353.84-410.57-577.16-572.73
Sale of Property, Plant & Equipment
2.530.160.611.259.380.11
Cash Acquisitions
-8,134-8,134-1,242---
Sale (Purchase) of Intangibles
-2,816-3,033-1,112-2,864-2,492-1,043
Investment in Securities
-1,289----1,583-
Other Investing Activities
-39.5919.2115.8224.48-13.3838.8
Investing Cash Flow
-13,629-12,468-2,691-3,249-4,656-1,577

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-3,9002,3781,2161,4351,291
Long-Term Debt Issued
-21,7222,95120,4766,2505,063
Total Debt Issued
28,78225,6225,32821,6927,6856,354
Short-Term Debt Repaid
--4,004-1,260-861.82-2,100-870.8
Long-Term Debt Repaid
--12,428-2,123-18,522-3,259-5,642
Total Debt Repaid
-16,138-16,432-3,382-19,384-5,359-6,513
Net Debt Issued (Repaid)
12,6449,1901,9462,3082,326-159.41
Issuance of Common Stock
1.396.770.260.6-1,414
Repurchase of Common Stock
--780.99----57.35
Common Dividends Paid
-1,520-1,520-1,232-906.23-506.06-92.01
Other Financing Activities
---0.31--558.27558.31
Financing Cash Flow
11,1256,896714.091,4031,2621,663

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
217.71-200.738119.9152.89-89.52
Net Cash Flow
2,2121,7104,259-212.5377.89116.49

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
3,1466,1625,8011,2043,142-453.07
Free Cash Flow Growth
-53.30%6.23%381.96%-61.70%--
Free Cash Flow Margin
11.04%30.05%31.21%7.10%21.47%-3.58%
Free Cash Flow Per Share
12.0423.5522.024.5912.01-1.76
Levered Free Cash Flow
-59.93,3683,200-4,2961,917-1,801
Unlevered Free Cash Flow
1,8323,9163,551-3,9632,139-1,634

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
2,7921,107495.06446.25290.7227.93
Cash Income Tax Paid
1,6861,301915.241,036444.89259.57
Change in Working Capital
-905.191,758-711.95-3,438-909.7-2,833